| Title: | Serum apolipoproteins and mortality risk: evidence from observational and Mendelian randomization analyses |
| Journal: | American Journal of Clinical Nutrition |
| Published: | 10 Jan 2024 |
| Pubmed: | https://pubmed.ncbi.nlm.nih.gov/38211689/ |
| DOI: | https://doi.org/10.1016/j.ajcnut.2024.01.002 |
Publication 8966
WARNING: the interactive features of this website use CSS3, which your browser does not support. To use the full features of this website, please update your browser.
Abstract
BACKGROUND: Apolipoproteins (APOs) have emerged as significant players in lipid metabolism that affects the risk of chronic disease. However, the impact of circulating APO concentrations on premature death remains undetermined.</p>
OBJECTIVES: This study aimed to investigate the associations of serum APOs with all-cause, cardiovascular disease (CVD)-related, and cancer-related mortality.</p>
METHODS: We included 340,737 participants who had serum APO measurements from the UK Biobank. Restricted cubic splines and multivariable Cox regression models were used to assess the associations between APOs and all-cause and cause-specific mortality by computing hazard ratios (HRs) and 95% confidence intervals (CIs). Based on 1-sample Mendelian randomization (MR) design, including 398,457 participants of White ancestry who had genotyping data from the UK Biobank, we performed instrumental variable analysis with 2-stage least squares regression to assess the association between genetically predicted APOs and mortality.</p>
RESULTS: After adjusting for potential confounders including high-density and low-density lipoprotein particles, we observed nonlinear inverse relationships of APOA1 with all-cause, CVD-related, and cancer-related mortality (P-nonlinear < 0.001). By contrast, positive relationships were observed for APOB and all-cause (P-nonlinear < 0.001), CVD-related (P-linear < 0.001), and cancer-related (P-linear = 0.03) mortality. MR analysis showed consistent results, except that the association between APOB and cancer mortality was null. Furthermore, both observational and MR analyses found an inverse association between APOA1 and lung cancer-related mortality (HR comparing extreme deciles: 0.46; 95% CI: 0.26, 0.80; and HR: 0.78; 95% CI: 0.63, 0.97, respectively).</p>
CONCLUSIONS: Our findings indicate that circulating APOA1 has potential beneficial effects on all-cause, CVD-related, and lung cancer-related death risk, whereas APOB may confer detrimental effects on all-cause and CVD-related death risk.</p>
8 Authors
- Jiacong Li
- Xianxiu Ge
- Xinyi Liu
- Chengqu Fu
- Junyan Miao
- Wei Zhao
- Lin Miao
- Dong Hang
1 Application
| Application ID | Title |
|---|---|
| 52217 | Serum cardiometabolic biomarkers in relation to all-cause and cause-specific mortality |
Enabling scientific discoveries that improve human health